Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo
Dendreon Corp. (NASDAQ: DNDN) has been facing problems getting its Provenge sales for advanced metastatic prostate cancer through to the market. Even a direct to consumer advertising campaign has so ...Read Full Story »







